^
    Back
    Association details:
    Biomarker:HYAL4 V1
    Cancer:Bladder Cancer
    Drug:gemcitabine (DNA synthesis inhibitor) +
    decitabine/ tetrahydrouridine (EPI01) (DNA methylation inhibitor, Cytidine deaminase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Clin Cancer Res
    Title:

    HYAL4-V1/Chondroitinase (Chase) Drives Gemcitabine Resistance and Predicts Chemotherapy Failure in Patients with Bladder Cancer

    Published date:
    05/24/2021
    Excerpt:
    CDA inhibitor Tetrahydrouridine re-sensitized V1-expressing cells to Gemcitabine...Low-dose combination of Gemcitabine and Tetrahydrouridine abrogated the growth of V1 tumors with minimal toxicity.
    DOI:
    10.1158/1078-0432.CCR-21-0422